IDEAYA Biosciences, Inc. — 2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual filing, not a standalone fourth-quarter report. IDEAYA is a clinical-stage precision oncology company with no approved products and no product-sales revenue.
Financial and liquidity summary
| Metric | 2020 | 2019 |
|---|---|---|
| Collaboration revenue | $19.5 million | None |
| Research and development expense | $39.7 million | $34.3 million |
| General and administrative expense | $15.2 million | $10.0 million |
| Operating loss | $35.3 million | $44.3 million |
| Net loss | $34.5 million | $42.0 million |
| Net loss per share, basic and diluted | $1.40 | $3.36 |
| Net cash from (used in) operating activities | $55.5 million | ($39.3 million) |
| Cash, cash equivalents and marketable securities at year-end | $283.6 million | $100.4 million |
2020 collaboration revenue was from the GSK collaboration, including research and development services and license-related revenue. Revenue recognized does not represent product sales. Operating cash flow was positive mainly because GSK’s $100 million upfront payment increased contract liabilities; it should not be read as evidence of cash-generative operations. Year-end contract liabilities were $83.8 million. The filing reports no borrowings; reported liabilities include contract liabilities and operating lease obligations, including $6.7 million in lease liabilities.
Changes versus 2019
- Collaboration revenue rose from zero to $19.5 million following the GSK agreement’s effectiveness in July 2020.
- Operating expenses increased 24% overall: R&D rose 16% to $39.7 million, and G&A rose 53% to $15.2 million. The operating loss narrowed to $35.3 million, and net loss narrowed by $7.5 million.
- R&D spending increased with program advancement and clinical/manufacturing startup work; COVID-related laboratory restrictions partly offset expense growth.
- Liquidity increased substantially, supported by the GSK upfront payment, a follow-on public offering, a private placement to GSK’s affiliate, and ATM sales. Financing activities provided $128.8 million in 2020.
Outlook, programs and risks
- Management estimated existing cash, equivalents and marketable securities would fund planned operations into 2024; the financial-statement note also states funding is expected for at least 12 months from issuance. The company expects continued, substantial losses and may need additional capital.
- IDE397: FDA-authorized Phase 1 trial, with first-patient dosing targeted for Q1 2021 and preliminary pharmacodynamic data targeted for the second half of 2021. The candidate targets MTAP-deleted tumors.
- IDE196: ongoing Phase 1/2 basket trial. The company reported one confirmed partial response among four evaluable skin-melanoma patients in an early cohort and observed early activity in the binimetinib combination arm; interim data were targeted for 2021. These are preliminary, small-cohort observations, not established efficacy.
- Preclinical pipeline includes PARG, Pol Theta, Werner helicase and DNA-damage-target programs. Development-candidate selection for PARG and Pol Theta was targeted for 2021.
- The GSK agreement provided a $100 million upfront payment and potential future option, milestone, profit-share and royalty economics. The MAT2A license depends on GSK exercising its option after receiving Phase 1 data; future payments are uncertain and subject to development and other conditions.
- COVID-19 had not materially affected the reported 2020 business or supply chain, but management warned that trial enrollment, site activity, manufacturing and timelines could be disrupted.
- Key risks include early-stage clinical and preclinical development, trial enrollment and safety, uncertain biomarkers and diagnostics, reliance on collaborators and third-party manufacturers, competition, intellectual-property protection, and the need for future financing. The company reported no material pending legal proceedings.
Important facts for investors to verify
- Confirm subsequent IDE397 and IDE196 trial starts, enrollment, safety, efficacy and data timing against later disclosures; compare final datasets with the preliminary observations described here.
- Track GSK’s MAT2A option decision and any changes to collaboration programs, cost-sharing obligations or expected economics.
- Reconcile reported operating cash flow with the GSK upfront payment, deferred contract liabilities and ongoing operating cash requirements.
- Review post-year-end ATM share sales: 2.71 million shares generated $43.3 million gross proceeds from January through March 22, 2021, adding dilution.
- Assess whether the stated runway assumptions remain valid as clinical, research, manufacturing and corporate spending evolve.